Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.
According to a new study published in the journal Cellular Signalling, cannabinoids may play a crucial role in preventing and ...
Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...
5d
News Medical on MSNAdrenomedullin hormone as key driver of insulin resistance in obesity-linked type 2 diabetesResearchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.
2d
AZoLifeSciences on MSNPanK4 identified as a regulator of glucose and lipid metabolismPhysical activity is not only important for fitness, but also for health. This is confirmed by a new study conducted under the direction of Prof. Dr. Maximilian Kleinert at the German Institute of ...
Onco-Innovations hebt drei Schlüsselaspekte der Studien hervor: Die Fähigkeit der Nanopartikel-Formulierung des PNKP-Wirkstoffs auf den Krebsherd abzuzielen; die Wirksamkeit dieser Formulierung als ...
Emittent / Herausgeber: MCS Market Communication Service GmbH / Schlagwort(e): Expansion/Studie Lizenzierte PNKP-Inhibitor-Technologie von Onco-Innovations erhöht in Tierstudie die ...
The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...
We developed a non-invasive imaging method to efficiently and rapidly visualize the pharmacodynamics of kinase inhibitors and degraders using an engineered kinase-modulated bioluminescent indicator.
In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results